Home / Research / Alzheimer / 


Alzheimer’s Disease is a progressive mental deterioration that can occur in middle or old age, due to generalized degeneration of the brain. It’s characterized by memory loss, confusion, and problems communicating.

Fernández-Ruiz, J; Moro, M. A; Martínez-Orgado, J (2015). “Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications”. Neurotherapeutics. 12 (4): 793–806. doi:10.1007/s13311-015-0381-7


Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., Muñoz, E., & Sagredo, O. (2015). "Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice". Neurotherapeutics, 12(1), 185-199.


Liu CS,Chau SA, Ruthirakuhan M, Lanctôt KL, Herrmann N4. (2015). "Cannabinoids for the Treatment of Agitation and Aggression in Alzheimers Disease." CNS Drugs. 29(8):615-23. doi: 10.1007/s40263-015-0270-y


Maroof N, Pardon MC, Kendall DA. (2013). "Endocannabinoid signalling in Alzheimers disease." Biochem Soc Trans. 41(6):1583-7. doi: 10.1042/BST20130140.


Aso E, Ferrer I. (2014)."Cannabinoids for treatment of Alzheimers disease: moving toward the clinic." Front Pharmacol. 5:37. doi: 10.3389/fphar.2014.00037. eCollection 2014.


*Current research does not guarantee that cannabinoids will cure any condition. However, a growing body of ongoing studies does suggest that these cannabinoids could offer treatment potential for a variety of physical and mental conditions.